Mok S C, Bell D A, Knapp R C, Fishbaugh P M, Welch W R, Muto M G, Berkowitz R S, Tsao S W
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts.
Cancer Res. 1993 Apr 1;53(7):1489-92.
The mutation of K-ras protooncogene was examined in 44 cases of borderline ovarian epithelial tumors and 18 cases of invasive ovarian carcinomas. In borderline tumors, K-ras mutations are a common feature, having been found in 21 of 44 cases (48%). Twenty of the 21 mutations were identified at codon 12, and one was identified at codon 13. A detailed analysis of the mutation pattern of K-ras revealed a close association with the histological cell types of the tumor. Mutation of K-ras was detected at a higher frequency in mucinous borderline tumor (identified in 12 of 19 cases) compared to serous borderline tumor (identified in 9 of 25 cases). K-ras mutation was also detected in invasive mucinous and serous ovarian carcinomas, hence supporting the notion that borderline ovarian tumors may represent a pathological continuum between benign and frankly invasive diseases.
对44例卵巢交界性上皮性肿瘤和18例浸润性卵巢癌进行了K-ras原癌基因突变检测。在交界性肿瘤中，K-ras突变是一个常见特征，44例中有21例（48%）检测到该突变。21例突变中有20例在密码子12处被鉴定，1例在密码子13处被鉴定。对K-ras突变模式的详细分析显示，其与肿瘤的组织学细胞类型密切相关。与浆液性交界性肿瘤（25例中有9例检测到）相比，黏液性交界性肿瘤中K-ras突变的检出频率更高（19例中有12例检测到）。在浸润性黏液性和浆液性卵巢癌中也检测到了K-ras突变，因此支持了卵巢交界性肿瘤可能代表良性和明显浸润性疾病之间病理连续体的观点。
